Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Open Access Highly Accessed Case report

Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood

Stefanie Boms1, Thilo Gambichler2*, Marcus Freitag1, Peter Altmeyer1 and Alexander Kreuter1

Author Affiliations

1 Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstr. 56, D-44791 Bochum, Germany

2 Department of Dermatology, Oldchurch Hospital, Waterloo Road, Romford, RM7 OBE, London, United Kingdom

For all author emails, please log on.

BMC Dermatology 2004, 4:14  doi:10.1186/1471-5945-4-14

Published: 14 October 2004

Abstract

Background

Lichen sclerosus is a chronic inflammatory disease with a predilection of the anogenital region. Because of the potential side effects of repeated local application of potent glucocorticosteroids, equally-effective, safer therapeutic options are required, especially in the treatment of children.

Case presentations

We report on the efficacy of twice-daily application of pimecrolimus 1% cream in four prepubertal girls (range of age: 4 to 9 years) who suffered from anogenital lichen sclerosus. After three to four-month treatment, all patients had almost complete clinical remission including relief from itch, pain and inflammation. Only minor improvement was observed for the white sclerotic lesions. No significant side effects have been observed.

Conclusions

Topical pimecrolimus appears to be an effective and safe treatment for children with anogenital lichen sclerosus. The clinical benefits observed in the four patient presented particularly include relief of pruritus, pain and inflammation. Vehicle-controlled studies on a larger number of patients are now warranted to substantiate our promising findings, and to investigate long-term efficacy and safety of topical pimecrolimus in anogenital lichen sclerosus.